Inhibition of Gsk3b Reduces Nfkb1 Signaling and Rescues Synaptic Activity to Improve the Rett Syndrome Phenotype in Mecp2-Knockout Mice by Jorge Torres, Olga C. et al.
ArticleInhibition of Gsk3b Reduces Nfkb1 Signaling and
Rescues Synaptic Activity to Improve the Rett
Syndrome Phenotype in Mecp2-Knockout MiceGraphical AbstractHighlightsd Gsk3b kinase activity and inflammation are increased in mice
models of Rett syndrome
d Specific inhibition of Gsk3b reduces motor deficits and
improves general well-being
d Neuronal morphology is restored in vitro and in vivo and
excitatory synapses altered
d Gsk3b is a potential therapeutic target in Rett syndrome
treatmentJorge-Torres et al., 2018, Cell Reports 23, 1665–1677
May 8, 2018 ª 2018 The Author(s).
https://doi.org/10.1016/j.celrep.2018.04.010Authors
Olga C. Jorge-Torres, Karolina Szczesna,






Rett syndrome (RTT) is a severe
neurodevelopmental disorder
characterized by loss-of-function
mutations in the MeCP2 gene. Jorge-
Torres et al. show that mice models of
RTT display hyperactivation of Gsk3b
kinase and neuroinflammation. Inhibition
of the Gsk3b pathway partially rescues
the phenotype and affects neuronal
morphology and synaptic activity.
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Rett syndrome (RTT) is the second leading cause of
mental impairment in girls and is currently untreat-
able. RTT is caused, in more than 95% of cases, by
loss-of-function mutations in the methyl CpG-bind-
ing protein 2 gene (MeCP2). We propose here a mo-
lecular target involved in RTT: the glycogen synthase
kinase-3b (Gsk3b) pathway. Gsk3b activity is de-
regulated in Mecp2-knockout (KO) mice models,
and SB216763, a specific inhibitor, is able to alleviate
the clinical symptoms with consequences at the
molecular and cellular levels. In vivo, inhibition of
Gsk3b prolongs the lifespan of Mecp2-KO mice
and reduces motor deficits. At the molecular level,
SB216763 rescues dendritic networks and spine
density, while inducing changes in the properties
of excitatory synapses. Gsk3b inhibition can also
decrease the nuclear activity of the Nfkb1 pathway
and neuroinflammation. Altogether, our findings
indicate that Mecp2 deficiency in the RTT mouse
model is partially rescued following treatment with
SB216763.
INTRODUCTION
Rett syndrome (RTT; OMIM #312750) is a rare neurodevelop-
mental pathology. It was first described in 1966 as a cognitive
impairment disorder affecting 1 in 10,000 female births (Rett,Ce
This is an open access article under the CC BY-N1966; Hagberg et al., 1983). In 1999, mutations in the
MeCP2 gene were found to be the genetic basis of most
cases of RTT (Amir et al., 1999). MeCP2 is a nuclear protein,
expressed widely in different tissues but most abundantly in
neurons of the mature nervous system, which had been iden-
tified a few years earlier by Bird and coworkers as a new pro-
tein that bound to the methylated CpG dinucleotides (Lewis
et al., 1992).
RTT is an X chromosome-linked, progressive disorder with
a normal prenatal and perinatal period. Rett patients have
proper brain development during the first few months of age,
achieving normal neurodevelopment, motor function, and
communication skills. However, developmental regression ap-
pears between 8 and 24 months of age (Trevathan and Naidu,
1988; Hagberg, 2002). RTT patients suffer from growth failure,
gastrointestinal problems, seizures, and respiratory and car-
diac abnormalities. Epilepsy is also one of the main symptoms,
with a frequency between 50% and 90% of all cases (Steffen-
burg et al., 2001; Huppke et al., 2007), although its severity
often tends to decrease after adolescence, with lower seizure
frequency and fewer secondary generalized seizures (Krajnc
et al., 2011).
Because glycogen synthase kinase-3B (GSK3B) has crucial
roles in neural development, including neurite growth, specifi-
cation, and synapse (Seira and Del Rı́o, 2014), we set out to
investigate its role in the pathophysiology of RTT. GSK3 is en-
coded by two genes, GSK3A and GSK3B, (Frame et al., 2001;
Doble and Woodgett, 2003). Both kinases are highly expressed
in the brain, but enhanced expression of GSK3B above physi-
ological levels results in hyperactivity and mania (Prickaerts
et al., 2006). GSK3 enzymes also have important functions asll Reports 23, 1665–1677, May 8, 2018 ª 2018 The Author(s). 1665
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
regulators of neurotransmitter signaling, as indicated by their
control of pathways downstream of dopamine receptors (Beau-
lieu et al., 2004).
GSK3B is deregulated by tyrosine and serine/threonine phos-
phorylation; specifically, phosphorylation in Ser9 correlates with
the inhibition of its kinase activity (Frame et al., 2001; Wang
et al., 1994; Harwood, 2001), while phosphorylation of tyrosine
in position 216 is associated with enhanced kinase activity.
Several kinases have been reported as targeting the site (Sayas
et al., 1999; Hartigan et al., 2001), and even an intramolecular
autophosphorylation event has been described (Cole et al.,
2004).
Overexpression of a constitutively active GSK3B in cultured
neurons reduces expression and clustering of the synaptic pro-
tein synapsin I (Zhu et al., 2007), while pharmacological inhibition
of GSK3B activity induces synapsin I clustering in developing
neurons (Hall et al., 2002). Moreover, activation of GSK3B re-
duces expression of postsynaptic markers and suppresses
release of presynaptic glutamate by inhibiting the synaptic
vesicle exocytosis in response to membrane depolarization
(Zhu et al., 2010). GSK3B negatively regulates synaptic vesicle
fusion events through interference with Ca2+-dependent SNARE
complex formation. Other studies have also reported functional
roles of GSK3B in the regulation of N-methyl-d-aspartic acid
(NMDA) receptor-dependent synaptic plasticity (Decker et al.,
2010; Peineau et al., 2008; Li et al., 2009). Activation of GSK3B
mediates induction of NMDA-dependent long-term depression
(LTD). In contrast, inhibition of GSK3B activity prevents LTD
and participates in long-term potentiation (LTP) induction (Hoop-
er et al., 2007). Importantly, an abnormal increase inGsk3b levels
and activity has been associated with neuronal pathologies, and
its inhibition has been proposed to be of therapeutic applicability
in Alzheimer’s disease (Medina and Avila, 2010) and fragile X
syndrome (Mines and Jope, 2011). Additionally, GSK3B is
involved in inflammation and oxidative damage in the brain,
which blocks the production of new neuronal connections in
the hippocampus, decreases plasticity and dendritic spine den-
sity, and manifests as unsocial behavior. Therefore, drugs that
inhibit GSK3B may also prove beneficial in RTT syndrome for
controlling cognitive impairments derived from excessive neuro-
inflammation (Jope et al., 2017).
Mecp2-knockout (KO) mice have a range of physiological and
neurological abnormalities that imitate the human syndrome.
Here we show that Gsk3b activity is increased in Rett Mecp2-
KO animals and that by targeting this pathway with a specific in-
hibitor (SB216763), it is possible to alleviate the symptoms and
increase the lifespan of the animals, reduce neuroinflammation
markers, and partially restore neuronal connectivity. This makes
the Gsk3b signaling pathway an attractive target for therapeutic
strategies.
RESULTS
Treatment with the Gsk3b Inhibitor SB216763
Prolongs Lifespan and Ameliorates RTT Symptoms in
Mecp2-Null Mice
Mecp2- KO mice develop a progression of symptoms in com-
parison with wild-type (WT) animals. KOmice are globally normal1666 Cell Reports 23, 1665–1677, May 8, 2018until 4 weeks of age; they then begin to suffer cognitive and mo-
tor dysfunctions and fully manifest the RTT-like phenotype at
about 6–8 weeks of age (Figure S1A). This leads to rapid weight
loss and death at approximately 10 weeks of age (Guy et al.,
2001).
To investigate the potential therapeutic role of inhibiting the
Gsk3b pathway, three different doses of the specific inhibitor
SB216763 were used for the optimization experiment: 0, 0.5,
and 1 mg/kg/day. During the whole experiment, none of the
selected doses induced a weight loss in the Mecp2-KO mice,
indicating that the drug was well tolerated and did not have
any negative effect on the animals’ lifespan in comparison with
the vehicle-treated Mecp2-KO group. A representative weekly
average for a dose of 0.5mg/kg/day is shown in Figure 1A, which
was subsequently used in all experiments and measurements.
After dose optimization, symptom onset was evaluated in the
SB216763-treated group compared with the vehicle-treated
group. In order to test the effect of the Gsk3b inhibitor
SB216763 on the symptoms of RTT mice, behavioral tests
were used regularly during the whole treatment procedure. We
started treatment when the animals were 4 weeks old, before
the onset of disease. The mice were treated daily during 6 weeks
and scored twice a week for neurological recovery following pre-
vious recommendations (Sutherland et al., 1993). To quantify the
alleviation of symptoms after drug administration, we measured
mobility, tremor, and breathing features and plotted the average
of each phenotypic score during each week of the treatment
normalized with the vehicle group (Figures 1B–1D). Treatment
with the Gsk3b inhibitor improved the general well-being of the
mice; the decrease in scores upon inhibitor treatment corre-
sponded to significant improvements in mobility, tremor, and
breathing phenotypes from 7 to 10 weeks of age by an average
of 50%–60%, with greater differences appearing at earlier ages.
Plotting of the average of the six scored symptoms to create a
total score showed a significant phenotypic improvement during
the whole time of treatment. SB216763 induced slower progres-
sion of the disease, and some of the treatedmice did not develop
any detectable symptoms until after 8 weeks of age (Figure 1E).
The vehicle group displayed an average lifespan of 70 days,
whereas in the SB216763-treated group, the average lifespan
was 91 days, (Figure 1F; Kaplan-Meier log rank test). Consid-
ering the whole population of SB216763-treated mice, the sur-
vival curve was 30% longer compared with the vehicle group.
Thus, the drug administration inMecp2-KOmice increased their
overall well-being by diminishing RTT symptomatology, with no
associated intrinsic toxicity, allowing the animals to live longer.
To address in an unbiased manner whether SB216763 admin-
istration is associated with reduction of themotor impairments in
the Mecp2-KO mice, we carried out bar-cross tests. KO mice
treated with the drug achieved better scores, suffering fewer
slips than vehicle-treated animals (Figures 1G and 1H). Again,
the recovery was more noticeable for younger mice. In neopho-
bia or Y-maze tests, we observed not only that themobility of the
KO mice was improved but also that their anxious behavior or
susceptibility to stress was reduced (Figures S1B–S1D). We
also assessed the effect of starting the treatment at a later
time point, from 6 weeks of age, when the symptoms were
already present in the animals. As shown in Figures S1E–S1I,
Figure 1. Treatment with the GSK3b Inhibitor SB216763 Ameliorates Symptoms and Prolongs Survival in Mecp2-KO Mice
(A) No effect on body weight was observed following drug treatment in KOmice, but KOmice displayed reduced body weight compared with WT animals (n = 10
for both control and treated animals).
(B–D) Bars showing improvement upon SB216763 treatment with respect tomobility (B), tremor (C), and breathing (D) scores (n = 25 for each experimental group).
(E) Representative plot of average total symptom scores. WT mice invariably score 0.
(F) Survival curve using vehicle- and SB216763-treated mice (n = 19 for each group). Log rank test (Mantel-Cox) was used to compare experimental groups, with
median survival of 72 days (for control mice) and 89 days (for drug-treated mice).
(G and H) Bar-cross test results show improvement upon treatment with SB216763. The test was carried out once per week; the time spent to cross the bar (G)
and number of slips (H) were quantified between the 7th and 10th weeks of age (n = 10 for each group).
Graphs represent mean ± SEM. For the described pairwise comparisons, a Tukey honest significant difference (HSD) post hoc test was performed after one-way
ANOVA. *p < 0.05 and **p < 0.01. See also Figure S1.drug administration at later times resulted in a slight tendency to-
ward improvement of the phenotype (although not statistically
significant).In view of these results, we went on to characterize changes in
the Gsk3b pathway following SB216763 administration at the
molecular and cellular level.Cell Reports 23, 1665–1677, May 8, 2018 1667
Figure 2. The Kinase Activity of GSK3b Increases in the Cerebellum of 8-Week-Old Mecp2/y Mice
(A and B) Analysis of Gsk3b expression in different mouse brain regions, male P56; sagittal hybridization-ISH (A) and graph displaying raw data (B) are shown.
Data are taken from the Allen Institute for Brain Science (available at http://mouse.brain-map.org).
(C) In vitro measurement of the kinase activity of Gsk3b from Mecp2 WT or KO mice brain regions. Graphs represent mean ± SEM; n = 3 per each group.
(D) Representativewesternblot of total andphosphorylatedGsk3b incerebellumextractsofWTorMecp2-KOmice. Phosphorylation of residuesTyr216 (indicative
of active protein) and Ser9 (indicative of inactive protein) were analyzed. The graphs represent the mean of values ± SEM for WT and KO (n = 2 per group).
(legend continued on next page)
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Activity of Gsk3b Is Upregulated in the Cerebellum of
Mice Models of RTT and in Human Post-mortem
Samples and Can Be Attenuated with SB216763
The Gsk3b protein is ubiquitously distributed in mammalian tis-
sues (Plyte et al., 1992), and its activity is an important compo-
nent in the regulation of complex functions (Grimes and Jope,
2001). The regulation of Gsk3b can occur through the phosphor-
ylation of specific residues, which may either activate or inacti-
vate the kinase. Inactivation can occur through phosphorylation
of serine-9 (Sutherland et al., 1993), serine-389, and threonine-
390 (Thornton et al., 2008), or threonine-43 (Ding et al., 2005),
while activation can occur through the phosphorylation of tyro-
sine-216 (Hughes et al., 1993).
Gsk3b mRNA is broadly distributed in normal mouse brain, as
shown by in situ hybridization (ISH) analysis in sagittal brain tis-
sue of P56 male mice. Regions with the highest signal include
the isocortex, the hippocampus, and the striatum (Figures 2A
and 2B; mouse Atlas Brain, http://mouse.brain-map.org). Com-
parison of Gsk3b kinase activity in several brain regions of
Mecp2-null mice against WT regions showed an abnormal in-
crease in Gsk3b activity, especially in the cerebellum (Figure 2C).
Although no changes in total Gsk3b protein level were observed,
we detected a 2-fold increase in the phosphorylation levels of
Tyr216 (which correlates with enhanced activity of the protein)
and a 2-fold decrease in the levels of Ser9 phosphorylation
(which attenuates activity) (Figure 2D), indicating that Gsk3b ac-
tivity is dysregulated in the cerebellum of the Mecp2/y mouse
model. Other brain regions of the same mice did not show this
pattern of activating phosphorylation (Figures S2A and S2B),
pointing to a cerebellum-specific upregulation of the Gsk3b
pathway. Male RTTmice models recapitulate most of the human
symptoms (Lombardi et al., 2015) but are arguably a limited
source of knowledge for the understanding of a disorder that af-
fects mainly females. We thus analyzed the levels of phosphory-
latedGsk3b in the cerebellum of 8-month-old (fully symptomatic)
heterozygousMecp2+/ female mice of the same strain. We also
observed an increase in the level of Gsk3b pTyr216 (Figure S2C).
Importantly, cerebellar extracts of post-mortem brains from Rett
patients displayed the same upregulation (Figure 2E), supporting
the idea that aberrant hyperactivation of GSK3 is a hallmark of
RTT. Because Akt is one of the main inhibitors of Gsk3b through
phosphorylation of Ser9 (Manning and Toker, 2017), these re-
sults are in accordance with the dysfunction of the Akt/mTOR
signaling pathway reported by others in Rett mice models (Ric-
ciardi et al.,2011). To confirm these observations, we established
neuronal primary cultures from either WT or Mecp2/y newborn
mouse brains and carried out immunofluorescence staining to(E) Analysis by western blot of cerebellar extracts from post-mortem human bra
amount) in Rett patients (aged 15–22 years) comparedwith control healthy sample
relative to total Gsk3b and loading control, representing the mean of values ± SE
(F) Immunostaining analyses in cerebellar neuronal primary cultures showed an inc
to decrease after treatment with the inhibitor, whereas the total Gsk3b (green) le
munostaining signal in each experimental group.
(G) Levels of Gsk3b pSer9 (red) were decreased in KO neurons but recovere
immunofluorescence ± SEM in all experimental groups.
Scale bars represent 10 mm; n = 15 pictures per condition, corresponding to app
were performed. *p < 0.05 and **p < 0.01. See also Figure S2.detect Gsk3b phosphorylated residues. As shown in Figures
2F and 2G, Gsk3b pTyr216 signal was increased and pSer9
signal was decreased in neuronal cultures derived from the
Mecp2-null brains, pointing to an enhanced activity of Gsk3b
also in these primary cultures. Remarkably, treatment of the cul-
tures with the Gsk3b inhibitor SB216763 partially restored both
signals to the levels of the WT neurons, with significant differ-
ences between the control-treated and the inhibitor-treated
Mecp2/y neurons.
Inhibition of Gsk3b Reduces Nfkb1 Signaling and
Inflammation Levels In Vivo
Gsk3b activation has been associated with increases in neuroin-
flammation andmicroglial activation, partly by enhancing the nu-
clear factor kappa b subunit 1 (Nfkb1) pathway (Wang et al.,
2010; Hoeflich et al., 2000; Ko et al., 2014). To test whether
this is the case in the RTT Mecp2-null mice model, we analyzed
nuclear Rela/p65 levels (indicative of the functional form as a co-
transcriptional regulator) by fluorescence staining in cerebellar
neuronal primary cultures. We found that nuclear p65 signaling
is upregulated in Mecp2-deficient neurons, whereas treatment
with SB216763 restored the WT localization (Figure 3A). Total
p65 levels were also increased in KO animals and could be
downregulated with the inhibitor, as seen in vivo by western
blot analysis of total brain protein extract from WT and Mecp2-
KO mice treated with the GSK3b inhibitor (Figure 3B).
Mecp2 depletion can trigger the dysregulation of inflammatory
responses and the activation of microglia (which is subsequently
lost as the disease progresses) in RTTmice models (Cronk et al.,
2015; Derecki et al., 2013). This is in accordance with previous
findings describing gliosis and cell loss in the cerebellum of
post-mortem RTT brains (Oldfors et al., 1990). In our study, anal-
ysis by immunofluorescence of the microglial marker Cd11b
showed high infiltration of microglial cells in the cerebellum of
8-week-old Mecp2-null mice, which was substantially reduced
in mice treated with Gsk3b inhibitor (Figure 3C). Similar results
were obtained in the analysis of the pons region next to the
cerebellum (Figure S3A). This was confirmed by qRT-PCR that
measured the levels of Cd11b mRNA (Figure 3D) and of the mi-
croglial activator Toll-like receptor 4 (Tlr4) (Figure 3E). To get a
broader view of the imbalance in inflammatory cell function and
of how SB216763 treatment could restore normal levels, we
used a commercial antibody array to interrogate 40 mouse cyto-
kines in the cerebellum ofMecp2-KO control or KO-treated mice
(Figures S3B and S3C). As shown in Figure 3F, inhibition of
Gsk3b downregulates a number of pro-inflammatory interleu-
kins, including IL-1a, IL-1b, IL-4, IL-12p70, IL-17, andKC/CXCL1.ins shows an increase in the levels of active Gsk3b (as indicated by pTyr216
s (n = 4 per group). The graph indicates quantitation of the intensity of the bands
M.
rease in the levels of Gsk3b pTyr216 (red) inMecp2-KO samples, which tended
vels did not change. Graphs represent the median intensity ± SEM of the im-
d upon drug treatment. Graphs below represent the quantification levels of
roximately 30 neurons. For statistical comparison, t test and one-way ANOVA
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Figure 3. SB216763 Treatment Reduces Inflammation Markers in RTT Model Mice and Primary Neuron Cultures
(A) Nuclear signal of Nfkb1 p65 decreases in KO primary neuron cultures upon treatment with Gsk3b inhibitor. Cells were immunostained with p65 antibody (red)
and counterstained with DAPI (blue). Graphs represent the median intensity (pixels) ± SEM of the immunostaining signal in each experimental group. Scale bar
represents 10 mm.
(B) Analysis by western blot indicates an increase of p65 levels in Mecp2-null total-brain extracts, whereas treatment with the Gsk3b inhibitor restores the WT
levels. The graph on the right indicates mean values ± SEM of the three biological replicates.
(C) SB216763-treated cells show attenuation of microglia migration after treatment. Representative immunostaining of Cd11b (microglial marker) in the cere-
bellum of sagittal sections counterstained with DAPI (blue). All images were processed with ImageJ Fiji version 1.50g. Scale bar represents 100 mm.
(D and E) Expression levels of Cd11b (D) and Tlr4 (E) in cerebellum extracts were determined by qRT-PCR. Mean values ± SEM are represented (n = 3 animals per
group).
(F) Comparison of the levels of a panel of cytokines in cerebellar extracts of 8-week-oldMecp2-KO control mice and KO-treated mice, as revealed by a cytokine
antibody array. Cytokines that went significantly down or up following treatment are indicated. Mean values ± SEM are indicated.
For statistical comparison, t test, one-way ANOVA, and Bonferroni’s multiple comparison as post hoc test were performed. *p < 0.05 and **p < 0.01. See also
Figure S3.Conversely, Fas ligand increases moderately in SB216763-
treated animals, which is indicative of the reaction to an exces-
sive immune response. Similarly, the anti-inflammatory cytokine1670 Cell Reports 23, 1665–1677, May 8, 2018IL-10 is also upregulated upon Gsk3b inhibition. IL-10 is known
to block NFKB1 activity and to be involved in the regulation of
the JAK-STAT signaling pathway (Mosser and Zhang, 2008).
Figure 4. Neuronal Morphology and Synaptic Activity upon In Vitro Treatment with the Gsk3b Inhibitor SB216763
(A) Alterations in the complexity of dendritic arborization and connectivity are partially restored with SB216763 treatment. Neurons were immunostained with
Map2 (red, left column), and a thresholding analysis with reconstruction of the dendritic network is also shown (right column). Graphs represent the average
branchpoints ± SEM. Scale bar represents 50 mm.
(B) Representative analysis of dendritic spine density inWT, control-treated, or SB216763-treatedKO primary neurons. Neuronswere immunostained withMap2,
pictures were obtained with a confocal microscope, and three-dimensional (3D) figures were obtained and analyzed using the Sholl algorithm. raph shows the
total spine count (mean ± SEM) in dendritic segments of 20 mm.
(C and D) The levels of Psd95 (C) and Bdnf (D) increase following treatment with the Gsk3b inhibitor. Pictures show representative immunostainings of total brain
primary cultures with Psd95 (red) and Bdnf (green) antibodies, counterstained with DAPI (blue). In all experiments, n = 10 pictures per condition, corresponding to
20–30 neurons. Quantification bars represent the integrated density (pixels) of signal using ImageJ Fiji version 1.50g. All data are represented as mean ± SEM.
Scale bars represent 10mm. For statistical comparison, one-way ANOVA and Bonferroni’s multiple comparison as post hoc test were performed. *p < 0.05 and
***p < 0.001.
(E–H) Spontaneous excitatory synaptic transmission recorded from cultured cerebellar granule neurons. (E) Miniature excitatory postsynaptic currents (mEPSCs)
recorded in primary neurons from WT mice (black) and KO mice (red) appeared at frequencies of 3 and 0.3 Hz, respectively. Treatment of KO cultures during
48 hr with 0.2 mM SB216763 before recording did not modify mEPSC frequency. (F) Average mEPSCs obtained from three different neurons in the indicated
conditions. Notice that mEPSCs are similar inWT and KO cultures, but treatment with 0.2mMSB216763 decreases the amplitude of spontaneous events. Dotted
lines indicate exponential fits to the decay phase of mEPSCs. (G) Distribution of mEPSC amplitudes in the indicated conditions. Solid lines show Gaussian fits for
(legend continued on next page)
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In Vitro Treatment with SB216763 Rescues
Arborization, Dendritic Spine Density, and Synaptic
Activity in Whole-Brain Primary Neuronal Cultures from
Mecp2/y Mice
We and others have shown that dendrite branching pattern and
density is significantly reduced in mice models and post-mortem
brain samples from RTT individuals (Szczesna et al., 2014; Arm-
strong et al., 1995; Bauman et al., 1995; Chapleau et al., 2009).
We thus wanted to test the effect of SB216763 treatment on
dendritic arborization and total spine count in neuronal primary
cultures. All neuronal branching was fluorescently labeled
when neurons reached 7 days in culture (DIV), using a polyclonal
antibody against Map2, a neuron-specific protein localized in
dendrites and dendritic spines (Morales and Fifkova, 1989). As
expected, there were significant differences in the branching
pattern and density of dendrites, with WT neurons displaying a
wider dendritic field than KO neurons. Treatment of Mecp2/y
neurons with SB216763 enabled an important recovery of den-
dritic arborizations and an improvement in spine density (Figures
4A and 4B).
We next performed a functional evaluation of the impact
of these morphological changes by measuring the expression
of some neuronal activity markers. Previous studies have
described differences in the levels of the postsynaptic density-
95 (Psd95) marker and brain-derived neurotrophic factor (Bdnf)
between the WT and the Mecp2-null RTT mice model, suggest-
ing a loss of synaptic connectivity and plasticity (El-Husseini
et al., 2000). Immunofluorescence staining in whole-brain pri-
mary cultures showed lower levels of Psd95 in Mecp2-null neu-
rons compared with WT cultures. Remarkably, treatment with
0.2 mM SB216763 recovered its expression to levels similar to
the WT condition (Figure 4C). We also investigated the levels of
Bdnf because it is a main target for Rett therapies and a signifi-
cant regulator of synaptic transmission and LTP, playing a role in
the formation of certain forms of memory (Leal et al., 2014). Of
note, signaling by Bdnf induces inhibition of Gsk3b (Mai et al.,
2002), raising the possibility that Bdnf deficiency contributes to
the higher kinase activity of Gsk3b. As shown in Figure 4D, treat-
ment with the Gsk3b inhibitor moderately recovered the levels of
Bdnf in primary cultures, pointing to an involvement of Gsk3b
signaling in Bdnf metabolism. To examine synaptic transmission
in cerebellar cultures, we recorded spontaneous neurotrans-
mitter release. We did not detect significant differences in inhib-
itory neurotransmission between WT and Mecp2-KO neurons
(Figures S4A–S4C), whereas the frequency of miniature excit-
atory postsynaptic currents (mESPCs) was severely decreased
in KO neurons (Figure 4E). This is in agreement with previous ob-
servations showing that hippocampal and cortical neurons in
Mecp2-KO mice display a decreased firing rate caused mainly
by alterations in excitatory neurotransmission (Chao et al.,
2007; Meng et al., 2016). Although treatment with SB216763
did not lead to an increase in the frequency of spontaneouseach experimental group. mEPSCs recorded after treatment with 0.2 mM SB21
mEPSCs decay times calculated from single exponential fits. mEPSCs recorded a
conditions.
See also Figure S4.
1672 Cell Reports 23, 1665–1677, May 8, 2018neurotransmitter release (Figure 4E), there was a noticeable
change in theminiature excitatory postsynaptic current (mEPSC)
profile following inhibition of Gsk3b, which modified amplitude
and decay time (Figures 4F–4H). These observations allow us
to speculate with the presence of specific drug-induced alter-
ations in excitatory neurotransmission that could be involved in
the partial rescue of the RTT phenotype in this mouse model.
Recovery of Spinogenesis and Synaptic Activity In Vivo
upon Inhibition of Gsk3b
The beneficial effects of SB216763 on the RTT phenotype was
finally tested in vivo by measuring dendritic spine formation. Us-
ing Golgi staining and the Sholl analysis algorithm (Rodriguez
et al., 2008), we found that RTT mice treated with SB216763
showed a significant increase in the number of spines in compar-
ison with vehicle-treated animals (Figure 5A). In accordance with
this observation, the expression of the dopamine receptor D2
(Drd2) (which elicits spine formation; Fasano et al., 2013) was
increased 2-fold in the treated animals (Figure 5B), indicating
that spinogenesis might be improved through inhibition of the
Gsk3b pathway. Neuronal arborization and spine density have
a direct link with synaptic activity, thus we next asked whether
SB216763 treatment could restore synaptic connectivity. We
examined the cell distribution pattern of presynaptic (Vglut1)
and postsynaptic (Psd95) markers specific to glutamatergic neu-
rons in WT and Mecp2-KO hippocampal tissue of mice brain
(Figure 5C). No significant changes were observed at the level
of Vglut1 expression, whereas levels of Psd95 were markedly
decreased in Mecp2-null tissues. Interestingly, treatment with
Gsk3b inhibitor partially restored the WT levels, confirming the
suitability of Gsk3b pathway inhibition as a means to reverse
the defects in synaptic activity present in RTT.
DISCUSSION
In this studywe examinedMecp2-null mice after treatment with a
Gsk3b inhibitor (SB216763) and provided in vivo and in vitro ev-
idence that the Gsk3b pathway is involved in the phenotype
arising from Mecp2 deficiency. A previous study has shown
that targeting Gsk3b in amousemodel of CDKL5 disorder (which
is characterized by Rett-like features) ameliorates neuronal
developmental defects (Fuchs et al., 2015). In accordance,
our data indicate that the phenotype of Mecp2-null mice is
partially reverted upon selective inhibition of the Gsk3b pathway.
Improvement of the motor abilities might be explained by the
specific cerebellar hyperactivation of Gsk3b that we have
observed in KO mice and Rett patients. Motor impairments
affect a patient’s quality of life severely, and our results suggest
that Gsk3b inhibitors might specifically affect this aspect of the
disorder. The best results were observedwhen treatment started
shortly after early development of the phenotype (at 4 weeks of
age), and administration starting at later time points showed6763 showed about half the size of control or KO neurons. (H) Distribution of
fter treatment with 0.2 mM SB216763 were longer lasting than in control or KO
Figure 5. Gsk3b Inhibition Improves
Neuronal Morphology and Connectivity
In Vivo
(A) Changes in dendritic spine density in a brain of
Mecp2-KO mice 4 weeks post-treatment with
Gsk3b inhibitor. Left: a representative picture of
dendritic segments in the midbrain region of
Mecp2-KO mice with or without treatment; right:
a 3D reconstruction of tracing dendrites. At least
ten neurons were analyzed from two animals per
group. Dendritic spine density in segments of
20 mm were analyzed after Golgi staining; the
graph shows the average of the total spine count
(mean ± SEM) for each condition.
(B) Expression levels of dopamine 2 receptor
(Drd2) mRNA in cerebellum, as assessed by qRT-
PCR, are increased upon Gsk3b inhibition (graph
represents mean values ± SEM, n = 2 per group).
(C) Analysis of neuronal activity markers in
the hippocampus of Mecp2-KO mice following
SB216763 administration. Pictures show a repre-
sentative staining of Psd95 (postsynaptic marker,
in red) and of Vglut1 (presynaptic marker, in green)
in the hippocampal region of WT, symptomatic
Mecp2-KO control mice, and SB216763-treated
KO mice (10 weeks old). The graphs represent the
integrated density (pixels) of positive signaling
using ImageJ Fiji version 1.50g.
All data are mean ± SEM from several replicas.
Scale bar represents 50 mm.weaker beneficial effects, indicating Gsk3b targeting might be
optimal at the early stages of the disease.
At the molecular level, we observed an abnormal hyperactiva-
tion of Gsk3b in KO mice, which is reverted with the specific in-
hibitor. These results may explain why previous studies suggest
that recombinant human insulin-like growth factor 1 (IGF1) may
ameliorate many clinical features of RTT (Khwaja et al., 2014).
IGF1 promotes mechanisms that can regulate the inactivation
of GSK3b via Ser-9 phosphorylation through direct interaction
with AKT (Grimes and Jope, 2001; Shaw et al., 1997; vanWeeren
et al., 1998).
Adownstream target ofGsk3b is the transcription factorNfkb1.
Recent research has shown abnormal activation of Nfkb1
signaling due to loss of Mecp2 regulation on Irak1 (a key compo-
nent of theNfkb1 pathway). Restoration of Irak1WT levels results
in improvement of dendritic complexity and extends lifespan of
Mecp2-deficient mice (Kishi et al., 2016). There is strong evi-Celldence suggesting a link between Gsk3b
and Nfkb1 activation and an increase in
inflammation in mice (Hoeflich et al.,
2000). We observed an attenuation of
Nfkb1 levels after treatment with Gsk3b
inhibitor and amarked decrease in inflam-
mation markers in the cerebellar area. We
specifically observed downregulation in
IL-1, IL-4, IL-12p70, and IL-17 levels
following treatment. Previous studies
have also shown increases in IL-4 and
IL-17 plasma levels in typical Mecp2-RTT patients and a general shift toward the Th2 subtype of
CD4+Tcells (Leoncini et al., 2015). In contrast, in peripheral blood
samples of CDKL5-RTT patients, both Th1- and Th2-related cy-
tokines were shown to be increased, revealing a complex dysre-
gulation of the cytokine repertoire in these closely related disor-
ders. In our hands, levels of typical microglial-related cytokines,
such as IL-1b, IL-12p70, and IL-10, were also affected by
Gsk3b inhibition. Evidence as to the role of microglial function
dysregulation in thedevelopment of diseasesof thecentral neural
system and of RTT in particular is growing, and the restoration of
Mecp2 levels in microglial cells has shown positive effects in
rescuing the phenotype (Maezawa and Jin, 2010; Lioy et al.,
2011; Derecki et al., 2012). These observations, together with
the glial infiltration shown in the cerebellar and pons area, rein-
force the idea that the pro-inflammatory status has an important
role in RTT and that inhibition of Gsk3b activity might reduce the
damaging effects of sustained neuroinflammation.Reports 23, 1665–1677, May 8, 2018 1673
An important finding of our work associated with Gsk3b inhibi-
tion is its ability to improve the neuronal dendritic network, sup-
ported by spin density measurements and higher levels of Drd2
receptor in vivo, placing Gsk3b as a target of potential therapeu-
tic interest to restore the synaptic plasticity deficiencies typical
of RTT (Figure S5). In this regard, the activity of Drd2 had already
been shown to depend on Gsk3b signaling (L’Episcopo et al.,
2012). At the electrophysiological level, we have observed that
inhibition of Gsk3b results in marked changes in the signature
of excitatory synapses. Targeted reexpression of Mecp2 in glu-
tamatergic neurons has been shown to rescue most of the RTT
phenotype in KO mouse models (Meng et al., 2016). Our results
thus underscore the relevance of the diminished excitatory
signaling in the pathophysiology of RTT and the importance of
regulating Gsk3b activity to modulate it. Some analogs of
SB216763 have been intensely studied in pre-clinical and clinical
assays for their therapeutic value in Parkinson’s and Alzheimer’s
diseases (Lovestone et al., 2015; Poewe et al., 2015). Although
the clinical efficacy has not been proved to date, their
administration to humans was acceptably safe. Our results
expand the potential applicability of such compounds, and we
propose that they might represent suitable therapeutic avenues
deserving further investigation in the context of RTT.
Overall, the findings reported suggest that the Gsk3b inhibitor
SB216763 is able to alleviate the clinical symptoms of the dis-
ease with consequences at the molecular and cellular levels in
the brain of Mecp2-null mouse models. The present work sets
the stage for additional research with Gsk3b inhibitors, including
dissection of mechanistic details as well as additional pre-clin-
ical testing.
EXPERIMENTAL PROCEDURES
Animals and Pharmacological Treatments
The experiments were performed on the B6.129P2(c)-Mecp2tm1+1Bird
mouse model for RTT (Guy et al., 2001). The mice were purchased from Jack-
son Laboratories (stock number 003890) andmaintained on a C57BL/6J back-
ground. All the animals were kept under specific pathogen-free conditions with
a 12 hr light-dark cycle, with drinking water and food available ad libitum. A to-
tal of 70 Mecp2/y (KO null male) and 20 WT mice were used in the study. Un-
less otherwise stated, treatment with SB216763 began at 4 weeks of age, and
mice received daily either an intraperitoneal (i.p.) injection of vehicle (20%
DMSO/saline) or SB216763 at a concentration of 0.5 mg/kg (catalog no.
S1075, diluted in DMSO 20%; Selleckchem). All procedures and experiments
were approved by the Ethics Committee for Animal Experiments of the
IDIBELL Centre, under the guidelines of Spanish laws concerning animal wel-
fare. The time points of animal treatment and tissue collection are summarized
in Figure S1. Samples from three control or three Mecp2+/ heterozygous fe-
male mice of the same strain were taken at 7 months of age, when the symp-
toms were fully developed.
Score Test
Progression of the RTT phenotype was monitored twice a week following a
three-point system (Guy et al., 2001). Neurological defects in KO mice were
scored blind to genotype and treatment status, focusing on mobility, gait, hin-
dlimb clasping, tremor, breathing, and general condition. Each of the six symp-
toms was scored from 0 to 2; 0 corresponds to the symptom’s being absent or
the same as in the WT, 1 to the symptom’s being present, and 2 to the symp-
tom’s being severe. The endpoint was reached when the animal score was 2
for each of the three last criteria (tremor, breathing, and general condition).
Additionally, if the animal lost 20% of its body weight during the experiment,
it was also sacrificed.1674 Cell Reports 23, 1665–1677, May 8, 2018Horizontal Bar-Cross Test
The test was carried out as described previously (Ferrer et al., 2005).
Gsk3b Activity Assay
We used the GSK-3b Activity Assay Kit protocol (CS0990; Sigma-Aldrich).
Protein extracts from the indicated brain regions were extracted from
8-week-old WT and KO mice using CelLytic M Cell Lysis Reagent (C2978;
Sigma-Aldrich). After immunoprecipitation of Gsk3b, kinase activity was as-
sayed by incubation with g-[32P]-ATP, and 32P incorporation was measured
in a Cerenkov counter. Gsk3b activity was expressed as enzymatic activity
with substrate minus enzymatic activity without substrate. All values for
each region from KO samples were normalized versus the same region in
WT samples.
Neuronal Culture
Primary cultures were prepared as described previously (Ahlemeyer and
Baumgart-Vogt, 2005). Dissociated cells were seeded at a final density of
7 3 105/well (six-well plate) previously coated with poly-D-lysine (1 mg/mL;
A003E; Merck). The cell culture was in neurobasal medium (Life Technologies)
supplemented with antibiotic (L0022; Biowest), GlutaMAX (35050; Life Tech-
nologies), and B27 (2%, supplement for neuronal culture; 17504; Life Technol-
ogies). AraC (5 mM cytosine arabinoside; 1768; Sigma) was added to the
culture medium 24 hr after plating to limit the growth of non-neuronal cells.
The medium was changed every 4–5 days, keeping 50% of the old medium
and adding the same volume of fresh medium. After 7 DIV, the neurons were
maintained in the same medium and treated with 0.2 mM SB216763. The
drugs were maintained in culture during 4 DIV.
Electrophysiology
All experiments were performed in thewhole-cell configuration of patch-clamp
mode using neurons cultured for 19 DIV. Typical resistances of pipettes used
for recordings were 5 MU when filled with internal solution composed of the
following: 110 mM CsCl, 4 mM MgCl2, 1 mM EGTA, 10 mM HEPES, 3 mM
Na2ATP, and 1 mM NaGTP (pH 7.2). The external solution contained
130 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 15 mM glucose, and
15 mM HEPES (pH 7.4). Recordings of mEPSCs were carried out at a holding
potential of70 mV in the presence of 50 mMbicuculine (Tocris) and 1 mMTTX
(Tocris). Recordings of spontaneous GABAergic miniature inhibitory postsyn-
aptic currents (mIPSCs) were obtained at 70 mV in the presence of 5 mM
CNQX (Tocris) and 1 mM TTX.
All salts were from Sigma-Aldrich. Before the addition of glucose and CaCl2,
the osmolality of the external solution was adjusted to 290 mOsm/kg. All ex-
periments were performed at room temperature (23C). Recordings were
made using an Axopatch-1D patch-clamp amplifier (Molecular Devices) under
the control of an ITC-18 board (Instrutech) driven by WCP software (Dr. John
Dempster, University of Strathclyde). Recordings were acquired at 10 kHz and
low-pass-filtered to 5 kHz. Analysis of mEPSCs and mIPSCs was carried out
using macros written in Igor Pro software.
Western Blot Cerebellum Total
Western blotting was carried out as previously described (Szczesna et al.,
2014). Specific primary antibodies used were Ms-Gsk3b (ab93926; Abcam),
Ms-Gsk3b pTyr279/216 (ab75745; Abcam), Rb-mAbGsk3b pSer9 (9323S;
Cell Signaling), Rb-CD11b (Ab133357; Abcam), Rb-Mecp2 (PAB0646; Ab-
nova), Rb-Nfkb P65 (sc-109; Santa Cruz), and b-actin peroxidase conjugated
(A3854; Sigma-Aldrich). All antibodies were used at dilutions recommended
by the manufacturers and incubated overnight at 4C in blocking buffer. The
quantification of the bands was performed using BIORAD Quantity One
version 4.6.5. In all cases, three WT and KO samples were evaluated, although
two samples are shown.
Brain post-mortem tissue from control or RTT patients was obtained from
the NIH NeuroBioBank at the University of Maryland, Baltimore, and at the Hu-
man Brain and Spinal Fluid Resource Center, VAWest Los Angeles Healthcare
Care Center, Los Angeles, which is sponsored by the National Institute of
Neurological Disorders and Stroke (NINDS)/National Institute of Mental Health
(NIMH), the National Multiple Sclerosis Society, and the Department of Veter-
ans Affairs.
Cytokine Antibody Array
Semiquantitative analysis of 40 inflammatory factors was performed using
the Mouse Inflammation Antibody Array Membrane (ab133999; Abcam).
Protein extracts from cerebellar tissue were obtained from 8-week-old
Mecp2-KO vehicle- or SB216763-treated animals using the 2X Cell Lysis
Buffer provided by kit. Protein extract from two mice in each group was
pooled into one sample and assayed according to the manufacturer’s in-
structions. Detection of all spots was done using the Amersham Imager
600 imaging system (GE Healthcare), and the integrated density of dots
was measured by densitometric analysis with ImageJ software. For each
spot, the raw numerical data were extracted and subjected to background
subtraction before normalizing the signal for each cytokine to the positive
control spots. The results were confirmed by visual comparison of the array
images.
Tissue and Primary Neuron Immunofluorescence
Tissue immunostaining was carried out as previously described (Szczesna
et al., 2014). The following primary antibodies were used: Ms-Gsk3b
(ab93926; Abcam), Rb-Gsk3b pTyr216 (ab75745; Abcam), Rb-mAbGsk3b
pSer9 (9323S; Cell Signaling), Rb-Nfkb p65 (6956; Cell Signaling), Rb-
CD11b (Ab133357; Abcam), Ms-Vglut1 (MAB5502; Millipore), Rb-Psd95
(2507; Cell Signaling), and Rb-Bdnf (ab108319; Abcam). Specific secondary
antibodies for each condition were used (Alexa Fluor 555 Rb-IgG, A21429,
Alexa Fluor 488 Ms-IgG, A21200; Life Technologies). All pictures were ob-
tained using a Zeiss microscope at 403 magnification and processed using
ImageJ Fiji version 1.50g. Tile images from sagittal brain sections were ob-
tained at 203 magnification using a Zeiss microscope. Z project and Tile
were carried out in order to get complete staining with all antibodies in a larger
area. Densitometric analysis was obtained as previously described (Szczesna
et al., 2014).
Analysis of Neuronal Morphology ‘‘In Vitro’’
Neuronal primary cultures from WT and KO animals were treated with 0.2 mM
SB216763, and the complexity of dendritic arborization and connectivity was
analyzed. After 7 DIV, the cell culture was fixed and immunostained with Rb-
Map2 antibody (ab5622; Abcam) (following the immunofluorescence staining
protocol described above). Pictures and z stacks were obtained using a Zeiss
Axio Observer Z1 microscope at 103 magnification with acquisition software
ZEN 2011. The images were processed using ImageJ Fiji version 1.50b (http://
imagej.nih.gov) using Auto-Threshold (algorithms Mean). Maximum-intensity
projection was used for the reconstruction of the three-dimensional dendritic
network using NeuronStudio software version 0.9.92. Automated segmenta-
tion was obtainedwith picture thresholding and Sholl analysis taking as a start-
ing point a soma and counting over a length of 20 mmwith concentric circles of
10 mm (Sholl, 1953).
Golgi Staining
The study of neuronal morphologies by Golgi staining was done as previously
described (Szczesna et al., 2014).
RNA Isolation and Real-Time qPCR Analysis
For total RNA preparation from whole brain or cerebellum, the RNeasy Lipid
Tissue Mini Kit (74804; QIAGEN) was used. RNA (2 mg) was retrotranscribed
using random hexamers with the ThermoScript RT-PCR System (Invitrogen).
Real-time PCR reactions were performed in triplicate on a Roche Lightcycler
480 machine. cDNA (50 ng) was amplified using the SYBR Green PCR Master
Mix (Life Technologies) in a final volume of 10 mL. All primer pairs were de-
signed with Primer 3 software and previously validated by gel electrophoresis
to amplify specific single products. All data were normalized with the following
endogenous controls: Rps28 and b-actin. The following primers were used:
Cd11b (forward CTGCCTCAGGGATCCGGAAAG, reverse TGTCTGCCTC
GGGGATGACATC), Tlr4 (forward GATTGCTCAAACATGGCAGTTTC, reverse
CATTCCAGGTAGGTGTTTCTGCTAA),Drd2 (forward ATCTCTTGCCCACTGC
TCTTTGGA, reverse ATAGACCAGCAGGGTGACGATGAA), Rps28 (forward
GGTGACGTGCTCACCCTATT, reverse CCAGAACCCAGCTGCAAGAT), and
b-actin (forward GTCGAGTCGCGTCCACC, GTCATCCATGGCGAACTGGT).Statistical Analysis
Bar graphics and statistical comparisons were obtained using GraphPad
Prism version 5.04. Comparative analyses between different experimental
groups were performed using unpaired Student’s t test and one-way
ANOVAwith Tukey’s or Bonferroni’s post hoc test for intergroup comparisons.
For the lifespan estimation, data were plotted in Kaplan-Meier survival curves,
using the log rank test for survival analysis, plotting survival (Y) as a function of
time (X). Results were considered significant if the p value was <0.05, <0.01,
or <0.001. Data are expressed as mean ± SEM.
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